There are better treatments for
menopause by Jonathan V. Wright, MD and
John Morgenthaler
No auto
mechanic in his right mind would replace
worn parts in a Mercedes with new parts
made for a Chevy. Unfortunately, many
physicians (and pharmaceutical
companies) seem to have less common
sense than the average auto mechanic
when it comes to treating menopausal
women.
The
"estrogen" replacement most doctors
prescribe today for menopausal and
premenopausal women is a pill known
generically as conjugated equine
estrogens (CEE). The best known brand of
CEE is Premarin®. Many studies suggest
that in many women, Premarin does help
reduce symptoms of menopause, including
hot flashes, vaginal thinning, memory
loss, and urinary incontinence. It also
appears to reduce the risk of developing
postmenopausal cardiovascular disease
(the leading killer of women) and
osteoporosis (the crippling progressive
bone weakness).
It also
may help to prevent a significant
proportion of Alzheimer's disease and
senile dementia.
Premarin is Horse Estrogen Derived From
Horse Urine
So what's
wrong with CEE? Take a close look at the
names. Notice the word "equine?" Yes,
that equine! Premarin is horse estrogen!
It is derived from the urine of pregnant
mares, hence, its brand name. Premarin
works great in female horses, just as
Chevy parts work great in Chevys. But
replacing human estrogens with horse
estrogens may be asking for trouble, and
here's why.
For the
last several million years, the human
female reproductive system has been
running quite well on three separate
estrogens: estriol, estrone, and
estradiol, which occur in an approximate
ratio of 90%:3%:7%1 (Fig. 1). Compare
that with Premarin, which consists of
estrone (75-80%), equilin (6-15%),
estradiol + two other equine estrogens
(5-19%).2 Notice that, in
addition to having larger proportions of
estrone and estradiol, Premarin also
contains equilin and two other forms of
estrogen found exclusively in horses.
The female
human body contains all the enzymes and
cofactors it needs to process estriol,
estrone, and estradiol — when they occur
in their natural human proportions. On
the other hand, it has none of the
enzymes and cofactors required to
metabolize equilin and the other horse
estrogens, nor does it have enough of
these important substances to deal with
the excessively large amounts of estrone
and estradiol found in Premarin (or in
the 100% estradiol "patch"). Horses, of
course, are well equipped to handle CEE.
The difference in reproductive hormones
is just one of many differences between
horses and humans. You may have noticed
that horses also have four hooves and a
mane, whereas human females don't.
It should
come as no surprise, then, that the
presence of Premarin in the human body
induces a hormonal imbalance that can
have important adverse consequences. To
physicians who prescribe Premarin, this
hormonal imbalance doesn't seem to carry
much weight. After all, the drug works,
doesn't it? But, as two leading
reproductive physiologists point out,
when women take Premarin, "Levels [of
equilin] can remain elevated for 13
weeks or more post-treatment due to
storage and slow release from adipose
[fat] tissue. In addition, metabolism of
equilin to equilenin and
17-hydroxyequilenin may contribute
greatly to the estrogen stimulatory
effect of [conjugated estrogen]
therapy." Another metabolite of equilin,
17- -dihydroequilin has been found to be
eight times more potent than equilin for
inducing endometrial growth, a possible
precursor to cancer.3
As a
result, Premarin produces "estrogenic
effects" that are much more potent and
longer lasting than those produced by
natural human estrogens.
This
explains why so many women feel
"unnatural" on Premarin, why Premarin
causes so many side effects and
discomforts (see box). It even explains
why Premarin has been associated with a
significant risk of breast and
endometrial cancer, because one of the
primary effects of equilin, estradiol
and estrone is to promote the growth of
tissue in the endometrial (uterine)
lining and also in the breast. This
growth is important for preparing the
premenopausal body for pregnancy and
lactation, but if some of that tissue
becomes cancerous or precancerous, look
out. According to Premarin's official
labeling, taking it for a year (without
also taking progesterone; see box),
increases a woman's risk of endometrial
cancer by as much as 14%.2
Most
conventional physicians, not to mention
the self-serving pharmaceutical
industry, are quick to rationalize the
cancer and other risks of horse
estrogens. Every treatment has its
risks, they point out, but the risk of a
postmenopausal woman dying of a heart
attack or stroke if she doesn't take
Premarin are far greater than her risk
of dying from cancer or an
osteoporosis-related fracture if she
does.
Why Not
Use Human Hormones For Humans
Well, this
reasoning is true as far as it goes, but
it ignores one hugely important fact —
horse hormones are not the only choice
human females have. What about human
hormones? Wouldn't it make more sense to
replace human estrogens with human
estrogens? Mercedes parts with Mercedes
parts? Of course, it does. The real
question is, why had no one thought of
this before?
This
realization occurred in 1982. All ob-gyn
textbooks discussed the naturally
occurring human estrogens — estriol,
estrone, and estradiol — but completely
neglected to recommend their use for
treating menopausal symptoms,
inexplicably recommending horse
estrogens instead!
The
approximate circulating levels of the
three estrogens were checked in human
females. This information was used to
design a combination estrogen
replacement regimen that closely matched
the natural conditions found in
premenopausal women. The result was
"triple-estrogen", a combination of
natural estriol, estrone, and estradiol
— using molecules identical in structure
to those produced in the human body — in
as close-to-natural quantities and
proportions as could be calculated (See
Figure. 1).
Triple
estrogen was formulated by a compounding
pharmacist friend, Ed Thorp of Kripps
Pharmacy, Vancouver BC, and the rest is
history. In the 16 years since triple
estrogen was first prescribed, thousands
of other progressive physicians — and
their grateful patients — have found
that it works as well as or better than
conventional ERT regimens, while
producing far fewer unwanted side
effects.
Estriol, the Missing-in-Action Hormone
You may
have noticed that one estrogen, estriol,
is completely absent from Premarin and
other forms of conventional estrogen
replacement regimens, although it
comprises as much as 80-90% of triple
estrogen. This is not an insignificant
omission. Estriol has long been
dismissed as a weak and unimportant
estrogen by most conventional physicians
and pharmaceutical researchers. They
have considered it to be primarily a
metabolite of estradiol and estrone,
which are far more potent in producing
estrogenic effects, such as inducing
endometrial tissue growth. "Why go
through all the trouble of putting
estriol into a pill if you don't really
need it?" seems to be their reasoning.
Well,
potency isn't everything. In fact,
estriol is vitally important precisely
because it is a weak estrogen. A number
of studies, published over four decades,
have demonstrated that estriol's unique,
and perhaps most important role, may be
to oppose the growth of cancer,
including cancer promoted by its more
potent cousins, estrone and estradiol.
We'll talk more about this in a moment.
Estriol
plays far more than just a defensive
role, though. European physicians have
been more open to the potential benefits
of estriol in menopausal women than
those in the US. As a result, most of
the clinical research evaluating estriol
has been conducted in Europe. In
general, these studies show that
menopausal women who use natural estriol
to replace their natural estrogen
experience a reduction in typical
menopausal symptoms, like hot flashes
and thinning of the vaginal tissue
(vaginal atrophy).4
In one
major trial, 22 practicing
gynecologists from 11 large
hospitals in Germany treated 911
perimenopausal women with estriol
and evaluated them regularly for 5
years. They found estriol to be
"very effective" against common
menopausal symptoms and
"well-tolerated" with "no
significant side effects."5
A
Swedish study evaluated 40
postmenopausal women with urinary
incontinence (leaky bladders) for up
to 10 years. The researchers found
that estriol treatment resulted in
significant improvement in 75% of
the women, including eight whose
ability to regulate urination
completely returned to normal.6
The
same Swedish study found that
symptoms of vaginal atrophy
disappeared in 79% of the women
after just 4 months of estriol
treatment. After 12 months, all but
one woman were symptom free.6
Built-in Cancer Protection
There is
no doubt that reasonable doses of horse
estrogens and 100% estradiol patches and
creams stimulate excessive proliferation
of endometrial cells, a precursor to
endometrial cancer. It is to reduce this
risk that any woman taking these drugs
must also take natural progesterone or a
synthetic progesterone substitute (or
"progestin") like the Provera® (see
box). This is in contrast to estriol,
which appears to actually antagonize the
proliferative effects of estrone and
estradiol, while having far less
tendency to stimulate endometrial
proliferation, itself. Studies in
experimental animals have shown that the
proliferative dose of estriol (the dose
that produces full endometrial growth)
is at least double that of horse
estrogens and estradiol.7
Estriol
apparently accomplishes its protective
role by benignly binding to estrogenic
receptors in the uterine lining and
possibly the breast. Unlike the more
potent estrogens, though, it does not
stimulate growth nearly as much. At the
same time, receptors covered by estriol
are shielded from more carcinogenic
estrone and estradiol.4 This is thought
to be the same mechanism by which other
weak estrogens, such as those found in
soy products, protect against cancer. In
laboratory animal studies totaling more
than 500 rat-years, estriol has been
shown to be the most protective estrogen
ever tested against cancers of the
breast induced by several potent
carcinogenic agents, including
radiation.8,9
There is
important evidence dating back to the
1960s suggesting that estriol may
protect against breast cancer as well.
At that time, Henry Lemon, MD, who was
head of the division of gynecologic
oncology at the University of Nebraska
College of Medicine, hypothesized that
some women who develop breast cancer
have too little estriol relative to
estradiol and estrone circulating in
their bodies. To test his hypothesis,
Dr. Lemon ran a preliminary study in
which he employed a urinary estrogen
quotient (EQ), which was simply a
measure of the ratio of estriol to the
total of estradiol + estrogen in the
urine over a 24-hour period; the higher
the quotient, the more estriol there is
relative to estradiol and estrone.10
In a small
study of 34 women with no signs of
breast cancer (Fig. 2), Dr. Lemon found
the EQ to be a median of 1.3 before
menopause and 1.2 after menopause. Only
21% of the women had an EQ <1.0 (ie,
estriol was less than estradiol and
estrone combined). For 26 women with
breast cancer, however, the picture was
quite different. Their median EQ was 0.5
before menopause and 0.8 after
menopause; 62% of these women had an EQ
<1.0. Thus, the women with breast cancer
seemed to be making substantially less
estriol relative to the other estrogens,
compared with the women without breast
cancer.
Over the
years some researchers have published
work disputing Dr. Lemon's findings,
while others have supported him. The
issue is complicated by the fact that a
woman's level of estriol when breast
cancer becomes apparent may not be as
important as a deviation from the norm
in her estriol levels as a young woman.
Clearly,
much more research, including
large-scale, long-term human trials are
needed to answer the many unanswered
questions regarding estriol's role in
cancer. In the meantime, there can be
little doubt that an estrogen
replacement regimen that includes the
three human estrogens in Triple estrogen
— estriol, estrone, and estradiol — in
identical-to-natural proportions is a
superior choice for perimenopausal and
postmenopausal women, compared with the
horse estrogens and 100%-estradiol
patches and creams the pharmaceutical
industry promotes.
This
sentiment was echoed in a 1978 editorial
in the Journal of the American Medical
Association titled, "Estriol, the
Forgotten Estrogen?" in which Alvin H.
Follingstad, MD, bemoaned the lack of
large clinical trials on estriol that
would earn it an FDA stamp of
"approval." "Do we as clinicians have to
wait the years necessary for the
completion of these trials before
estriol becomes available to us?" he
asked. "I think not. Enough presumptive
and scientific evidence has been
accumulated that we may say that orally
administered estriol is safer than
estrone and estradiol."11
Two
decades later, we are still waiting for
those clinical trials, and what Dr.
Follingstad said then is even more true
today. There's nothing to be gained by
waiting. If a woman is concerned about
her risk of cancer from estrogen
replacement (and who isn't?), then the
logical choice (considering both modern
scientific research and hundreds of
thousands of years of human experience
producing and metabolizing estrogens) is
an estrogen formula containing a
majority of estriol — in other words,
triple estrogen.
Natural
hormone formulations like triple
estrogen are normally available in the
US only from compounding pharmacies with
a physician's prescription, they can not
be found at standard pharmacies. You can
also order triple estrogen cream from
some overseas pharmacies. See our page
called, "How to Order Your
Pharmaceuticals from Overseas."
Natural
Progesterone can be purchased in many
health food stores or by mail order. See
our page called, "Where to Get Your
Nutritional Supplements."
The
Business of Menopause
If triple
estrogen is so much better than Premarin,
why have so few people heard about it?
The answer to this question can be
summed up in one word: patentability.
Premarin is patentable, and hence, can
be sold exclusively only by its
manufacturer and licensees, whereas
triple estrogen is a natural product,
like vitamin C, and can be sold by
anyone. Patentability has made Premarin
a huge moneymaker for its manufacturer,
Wyeth-Ayerst Pharmaceuticals. For nearly
30 years, it has been at or near the top
of the drug bestseller list. In just the
first half of 1997, pharmacists filled
22.1 million prescriptions for Premarin,
amounting to revenues of $388.2 million
in the United States alone. Add in the
rest of the world's women, and you get a
sense of the high stakes involved in the
business of menopause.
These
enormous financial resources have
provided Wyeth-Ayerst the muscle to
practically corner the estrogen market.
Through advertising, sponsorship of
clinical trials, and conferences, free
samples, and other common marketing
techniques, they have created an
atmosphere in which physicians virtually
equate estrogen replacement with
Premarin.
Most physicians, who
have little enough time to keep up with
the world of double-blind,
placebo-controlled drug trials reported
in medical journals — which are
supported largely by pharmaceutical
advertising — are completely in the dark
about the use of Triple estrogen and
other natural hormones. Their use is not
taught in medical schools, nor is it
promoted by any large pharmaceutical
companies. With no money available to
pay the enormous costs, the large,
definitive studies that might
demonstrate the efficacy and safety of
these natural hormone regimens will
likely never be done.
Open 9:00 am to 5:00 pm
(CT)
Monday through Friday
Closed on major U.S. holidays
Our 100%
Satisfaction Guarantee.
If you are not delighted with anything you purchase from us, let us
know, and we'll do our best to fix it for you.
Disclaimer:
Any health related information is for educational purposes only.
None of the information provided here is to be construed as medical
advice. Before applying any therapy or use of herbs, you may want to
seek advice from your health care professional. The information on
our website should not be a substitute for physician evaluation or
treatment by a health care professional and is not intended to
provide or confirm a diagnosis.